LAURA PETERSEN to Costs and Cost Analysis
This is a "connection" page, showing publications LAURA PETERSEN has written about Costs and Cost Analysis.
Connection Strength
0.046
-
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
Score: 0.032
-
The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997 Jan 22-29; 277(4):307-11.
Score: 0.008
-
Physician reporting compared with medical-record review to identify adverse medical events. Ann Intern Med. 1993 Sep 01; 119(5):370-6.
Score: 0.006